Subscribe
shutterstock_1123492958_willy_barton
Willy Barton / Shutterstock.com
7 May 2019Americas

GSK ordered to pay Vectura $89.7m in patent damages

British drugmaker  Vectura has succeeded in its  patent litigation against fellow UK pharmaceutical company  GlaxoSmithKline (GSK) over a series of drugs delivered through GSK’s ‘Ellipta’ dry powder inhaler.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Vectura wins additional $10m patent damages against GSK
16 September 2019   A district court has upped Vectura’s award of $89.7 million in damages by $10m, after a jury trial earlier this year found that GlaxoSmithKline has willfully infringed one of its patents.
Big Pharma
GSK awarded Arrow declaration in patent dispute with Vectura
17 December 2018   The English High Court has ruled in favour of GSK in its patent dispute with Vectura, a UK-based pharmaceutical company which specialises in inhalable medicaments.
Americas
Vectura sues GSK for patent infringement
29 July 2016   Pharmaceutical company Vectura has sued GSK for allegedly infringing its patent after claiming that it refused to expand on a licensing agreement.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
Vectura wins additional $10m patent damages against GSK
16 September 2019   A district court has upped Vectura’s award of $89.7 million in damages by $10m, after a jury trial earlier this year found that GlaxoSmithKline has willfully infringed one of its patents.
Big Pharma
GSK awarded Arrow declaration in patent dispute with Vectura
17 December 2018   The English High Court has ruled in favour of GSK in its patent dispute with Vectura, a UK-based pharmaceutical company which specialises in inhalable medicaments.
Americas
Vectura sues GSK for patent infringement
29 July 2016   Pharmaceutical company Vectura has sued GSK for allegedly infringing its patent after claiming that it refused to expand on a licensing agreement.

More on this story

Big Pharma
Vectura wins additional $10m patent damages against GSK
16 September 2019   A district court has upped Vectura’s award of $89.7 million in damages by $10m, after a jury trial earlier this year found that GlaxoSmithKline has willfully infringed one of its patents.
Big Pharma
GSK awarded Arrow declaration in patent dispute with Vectura
17 December 2018   The English High Court has ruled in favour of GSK in its patent dispute with Vectura, a UK-based pharmaceutical company which specialises in inhalable medicaments.
Americas
Vectura sues GSK for patent infringement
29 July 2016   Pharmaceutical company Vectura has sued GSK for allegedly infringing its patent after claiming that it refused to expand on a licensing agreement.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB